Latest news with #PSTV
Business Insider
6 days ago
- Business
- Business Insider
Plus Therapeutics reports Q1 EPS ($1.19) vs. (75c) last year
The company recognized $1.1M in grant revenue in the first quarter of 2025 compared to $1.7M in in the first quarter of 2024, which represents CPRIT's share of the costs incurred for the REYOBIQ platform advancement for the treatment of patients with LM. 'We improved our cash position in the first quarter as a result of both a financing and grant support,' said Marc Hedrick, M.D., Plus Therapeutics (PSTV) President and Chief Executive Officer. 'With the additional cash and further anticipated grant support in 2025, we are well positioned to make solid progress in our 2 key business goals: enrollment in our REYOBIQ CNS cancer radiotherapeutic clinical trials and the planned launch of the CNSide cerebral spinal fluid assay platform.' Confident Investing Starts Here:
Yahoo
6 days ago
- Business
- Yahoo
Plus: Q1 Earnings Snapshot
HOUSTON (AP) — HOUSTON (AP) — Plus Therapeutics, Inc. (PSTV) on Friday reported a loss of $17.4 million in its first quarter. The Houston-based company said it had a loss of $1.19 per share. Losses, adjusted for non-recurring costs, came to 56 cents per share. The developer of cell therapies posted revenue of $1.1 million in the period. _____ This story was generated by Automated Insights ( using data from Zacks Investment Research. Access a Zacks stock report on PSTV at Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
6 days ago
- Business
- Yahoo
Plus: Q1 Earnings Snapshot
HOUSTON (AP) — HOUSTON (AP) — Plus Therapeutics, Inc. (PSTV) on Friday reported a loss of $17.4 million in its first quarter. The Houston-based company said it had a loss of $1.19 per share. Losses, adjusted for non-recurring costs, came to 56 cents per share. The developer of cell therapies posted revenue of $1.1 million in the period. _____ This story was generated by Automated Insights ( using data from Zacks Investment Research. Access a Zacks stock report on PSTV at Sign in to access your portfolio
Yahoo
14-05-2025
- Business
- Yahoo
Plus Therapeutics (PSTV) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
Plus Therapeutics (PSTV) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended March 2025. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price. The stock might move higher if these key numbers top expectations in the upcoming earnings report. On the other hand, if they miss, the stock may move lower. While management's discussion of business conditions on the earnings call will mostly determine the sustainability of the immediate price change and future earnings expectations, it's worth having a handicapping insight into the odds of a positive EPS surprise. This developer of cell therapies is expected to post quarterly loss of $0.17 per share in its upcoming report, which represents a year-over-year change of +77.3%. Revenues are expected to be $1.85 million, up 10.1% from the year-ago quarter. The consensus EPS estimate for the quarter has been revised 31.25% higher over the last 30 days to the current level. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period. Investors should keep in mind that an aggregate change may not always reflect the direction of estimate revisions by each of the covering analysts. Estimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. This insight is at the core of our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction). The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier. Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only. A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). Our research shows that stocks with this combination produce a positive surprise nearly 70% of the time, and a solid Zacks Rank actually increases the predictive power of Earnings ESP. Please note that a negative Earnings ESP reading is not indicative of an earnings miss. Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and/or Zacks Rank of 4 (Sell) or 5 (Strong Sell). For Plus, the Most Accurate Estimate is lower than the Zacks Consensus Estimate, suggesting that analysts have recently become bearish on the company's earnings prospects. This has resulted in an Earnings ESP of -45.46%. On the other hand, the stock currently carries a Zacks Rank of #2. So, this combination makes it difficult to conclusively predict that Plus will beat the consensus EPS estimate. Analysts often consider to what extent a company has been able to match consensus estimates in the past while calculating their estimates for its future earnings. So, it's worth taking a look at the surprise history for gauging its influence on the upcoming number. For the last reported quarter, it was expected that Plus would post a loss of $0.51 per share when it actually produced a loss of $0.67, delivering a surprise of -31.37%. The company has not been able to beat consensus EPS estimates in any of the last four quarters. An earnings beat or miss may not be the sole basis for a stock moving higher or lower. Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors. Similarly, unforeseen catalysts help a number of stocks gain despite an earnings miss. That said, betting on stocks that are expected to beat earnings expectations does increase the odds of success. This is why it's worth checking a company's Earnings ESP and Zacks Rank ahead of its quarterly release. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported. Plus doesn't appear a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release. Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Plus Therapeutics, Inc. (PSTV) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
